Galluzzo S, Santini D, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells:an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets,2007;11(7):941-954.

Hewitt RE, Lissina A, Green AE, et al. The bisphosphonate acute phase response:rapid and copious production of proinflammatory cytokines by peripheral blood γδT cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol,2005;139(1):101-111.

Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol,2006;17(6):897-907.

Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int,2007;18(8):1023-1031.

Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab,2010;95(9):4380-4387.

Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf,2007;30(9):755-763.

Anastasilakis AD, Polyzos SA, Delaroudis S, et al. The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass. Clin Endocrinol (Oxf),2012;77(6):816-822.

Rossini M, Adami S, Viapiana O, et al. Long-term effects of amino-bisphosphonates on circulating gammadelta T cells. Calcif Tissue Int,2012;91(6):395-399.

Bertoldo F, Pancheri S, Zenari S, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res,2010;25(3):447-454.

Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr,2006;84(1):18-28.

Shidara K, Inaba M, Okuno S, et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int,2008;82(4):278-287.

Nowak Z, Konieczna M, Saracyn M, et al. Tartrate resistant acid phosphatase——TRACP-5b as a modern bone resorption marker. Pol Merkur Lekarski,2008;24(142):351-354.

Qin YJ, Zhang ZL, Zhang H, et al. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women. Acta Pharmacol Sin,2008;29(12):1493-1498.

D'Amelio P, Grimaldi A, Di Bella S, et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity:a key mechanism in osteoporosis. Bone,2008;43(1):92-100.

Cao Y, Liu X, Xu H. Utility of serum tartrate-resistant acid phosphatase isoform 5b, bone alkaline phosphatase and osteocalcin in osteoporotic fractures in Chinese patients. Clin Lab,2012;58(7-8):845-850.

Lencel P, Magne D. Inflammaging:the driving force in osteoporosis? Med Hypotheses,2011;76(3):317-321.

Gao Y, Grassi F, Ryan MR, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest,2007;117(1):122-132.

Pino AM, Rios S, Astudillo P, et al. Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. J Bone Miner Res,2010;25(3):492-498.

Kudo O, Fujikawa Y, Itonaga I, et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol,2002;198(2):220-227.

Pfeilschifter J, Koditz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev,2002;23(1):90-119.

Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss:an inflammatory tale. J Clin Invest,2006;116(5):1186-1194.

Cauley JA, Danielson ME, Boudreau RM, et al. Inflammatory markers and incident fracture risk in older men and women:the Health Aging and Body Composition Study. J Bone Miner Res,2007;22(7):1088-1095.